PMC3151517_01
Images of the left eye at presentation. (a) Fluorescein angiography shows multiple, punctate, hyperfluorescent RPE changes and optic nerve hyperfluorescence. (b) Optical coherence tomography shows subretinal fluid in the macula.
CRIM2011-747648.001.jpg
PMC3151517_01_CRIM2011-747648.001.jpg
fig1
Fluorescein angiography (FA) and ocular coherence tomography (OCT) showed subretinal fluid consistent with exudative RD (Figure 1; left eye).
Images of the left eye after a 5-month loss to follow-up (the visual acuity was finger counting). (a) Fluorescein angiography shows an active CNVM. (b) Optical coherence tomography shows a parafoveal CNVM and mild intraretinal fluid.
CRIM2011-747648.002.jpg
PMC3151517_01_CRIM2011-747648.002.jpg
fig2
After a 5-month loss to follow-up (without immunosuppressive treatment for the last 2 months), the patient returned with recurred inflammation, 20/25 vision in the right eye, and finger counting (CF) vision in the left eye because of a parafoveal CNVM with mild intraretinal fluid (Figure 2).
Images of the left eye 12 months after the third ranibizumab injection. (a) Color fundus photo shows retinal hemorrhage surrounding a CNVM, hyperpigmented macular RPE, and peripheral RPE hypopigmentation. (b) Fluorescein angiography shows a CNVM and hyperfluorescent, peripheral RPE changes. (c) Optical coherence tomography shows a parafoveal CNVM with a significantly increased amount of intraretinal fluid (compare with Figure 2(b)).
CRIM2011-747648.003.jpg
PMC3151517_01_CRIM2011-747648.003.jpg
fig3
Twelve months after the third injection, although the inflammation was controlled with MTX, vision in the left eye had again decreased to CF due to subretinal hemorrhage, increased amount of intraretinal fluid, and a recurrent CNVM (Figure 3).